Bayer
NEWS
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.
Bayer is moving closer to a $10 billion settlement over the Roundup lawsuits and the company is in the midst of restructuring.
Bayer and Meiogenix, a biotech company focused on next-generation breeding technologies, announced a collaboration to advance agricultural research and development by accelerating the development of Meiogenix’s proprietary technologies related to plant breeding and genome editing applications.
It was another busy week for clinical trial updates. Here’s a look.
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregivers living with liver cancer.
First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities
Here’s a look at the top 10 companies noted in the BioSpace Ideal Employer 2019 survey for being the most innovative and what they’ve been up to recently.
“We are excited to sign this acquisition agreement with Bayer, allowing us to have quick access to high-quality drug product manufacturing capacities and capabilities,” said Chris Chen, chief executive officer of WuXi Biologics.
JOBS
IN THE PRESS